Key statistics
On Friday, Jazz Pharmaceuticals PLC (J7Z:DUS) closed at 111.70, -9.92% below its 52-week high of 124.00, set on Nov 08, 2023.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 109.70 |
---|---|
High | 111.70 |
Low | 109.70 |
Bid | 114.70 |
Offer | 115.90 |
Previous close | 108.90 |
Average volume | 45.20 |
---|---|
Shares outstanding | 61.75m |
Free float | 61.27m |
P/E (TTM) | 17.41 |
Market cap | 7.63bn USD |
EPS (TTM) | 7.10 USD |
Data delayed at least 15 minutes, as of Nov 08 2024 15:00 GMT.
More ▼
Press releases
- Jazz Pharmaceuticals Announces Third Quarter 2024 Financial Results
- Jazz Pharmaceuticals Presents New Data at Psych Congress 2024 Confirming Xywav® (calcium, magnesium, potassium, and sodium oxybates) Oral Solution Treatment Benefits in Narcolepsy and Idiopathic Hypersomnia
- Jazz Pharmaceuticals to Report 2024 Third Quarter Financial Results on November 6, 2024
- PharmaMar Announces Positive and Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Jazz Pharmaceuticals Announces Statistically Significant Overall Survival and Progression-Free Survival Results for Zepzelca® (lurbinectedin) and Atezolizumab Combination in First-Line Maintenance Therapy for Extensive-Stage Small Cell Lung Cancer
- Jazz Pharmaceuticals Presents Updated Phase 2 Data for Zanidatamab Demonstrating Increased mPFS in HER2-Positive Metastatic Gastroesophageal Adenocarcinoma at ESMO 2024
- Jazz Pharmaceuticals to Present Advancements in Solid Tumor Oncology Research at ESMO 2024
- Jazz Pharmaceuticals to Present New Data Demonstrating Improved Epilepsy Outcomes with Epidiolex®/Epidyolex® (cannabidiol) at the European Epilepsy Congress 2024
- Jazz Pharmaceuticals Announces Pricing of Private Offering of $850 Million of 3.125% Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
- Jazz Pharmaceuticals Announces Private Offering of $850 Million of Exchangeable Senior Notes due 2030 and Concurrent Ordinary Share Repurchases
More ▼